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Abstract 
BACKGROUND: Non-Hodgkin Lymphoma (NHL) is a malignant haematological disease originates in the 
lymphocytes, caused by an abnormality in lymphocytes development which forms a tumour and may become 
cancer. Chemotherapy is the main treatment modality for aggressive lymphoma, but only a few patients achieve 
remission. Several factors such as age, clinical stadium, number of extranodal regions, and Lactate 
Dehydrogenase (LDH) level played a role in determining response to chemotherapy.  
AIM: To measure the association between LDH levels to prognosis of NHL in elderly patients who treated with 
rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in Sanglah General 
Hospital. 
METHODS: This study used a retrospective descriptive study on elderly NHL patients in Sanglah General 
Hospital from January until December 2014. The evaluation was measured using the IPI score to determine the 
prognosis of patients. Demographic data, the stadium, extranodal region, LDH level, and response to 
chemotherapy were recorded. 
RESULTS: Twenty-five patients were included in the study. The age ranged was between 61-76 years old (Mean 
65,68 ± 4,7 years; Median 65 years). The number of male patients was 19 (76%). Diffuse Large B-Cell Lymphoma 
(DLBCL) is the most common histopathological structure observed on the patients (68%). LDH levels were normal 
in 51.6% of the patients and considered high in the rests (48.4%). Results of the chemotherapy were a good 
response in 72.2%. Compared to the patients who showed complete response to chemotherapy, patients with no 
response (partial response and progression) had significantly higher levels of LDH (OR: 13,1; 95%CI: 1,36-
126,30; p = 0,001). 
CONCLUSION: Non-Hodgkin Lymphoma in elderly patients with no response to chemotherapy had significantly 
higher levels of LDH than patients with complete response. 
 
 
 
Introduction 
 
Lactate dehydrogenase (LDH) is a metabolic 
enzyme widely expressed in different tissues and is 
detectable in serum, which catalyses the 
interconversion of pyruvate and lactate during 
glycolysis and gluconeogenesis [1]. Since a long time, 
it has been observed that a high level of serum LDH is 
seen in patients with different malignancies. Increased 
LDH levels have been reported in solid tumours, 
leukaemia and diffuse lymphoma, particularly Burkitt’s 
lymphoma, although correlation has been established 
with any specific neoplastic disease or with any 
clinical or histologic parameter. The elevation of LDH 
in the blood is a relatively nonspecific phenomenon; 
however, it has been recognized as a tumour marker, 
as it reflects tumour burden and cellular turnover in 
several aggressive malignancies, including germ cell 
tumours [2], sarcomas [3], [4] and non-Hodgkin 
lymphoma (NHL) [5], [6].  
Patients with elevated serum LDH at the time 
of initial diagnosis have inferior survival outcomes, 
compared to those with normal LDH levels. Therefore, 
LDH has been a component of the International 
Prognostic Index (IPI) [7], a clinical tool for predicting 
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the prognosis of patients with aggressive NHL. 
However, the role of serum LDH beyond initial 
diagnosis, i.e. during active chemotherapy and the 
post-treatment follow-up period, has not yet been well 
defined.  
In this study, we conducted a retrospective 
analysis of the prognostic role of serum LDH after the 
treatment of elderly patients within a homogeneous 
disease population of NHL, undergoing a standard 
treatment, three weekly treatments of rituximab with 
cyclophosphamide, doxorubicin, vincristine and 
prednisolone (R-CHOP) immunochemotherapy.  
 
 
Material and Methods 
 
Among the patients who fulfilled the inclusion 
criteria, patients who underwent LDH testing after R-
CHOP therapy were selected. The LDH level was 
tested no more than 5 days after therapy. This study 
used a retrospective descriptive study on elderly NHL 
patients in Sanglah General Hospital from January 
until December 2014. The evaluation was measured 
using the IPI score to determine the prognosis of 
patients. Demographic data, histopathology, ECOG 
performance status, standard IPI, LDH level, and 
response to chemotherapy were recorded. We used 
RECIST (Response Evaluation Criteria in Solid 
Tumours) criteria for response therapy result.  
 
 
Results 
 
Twenty-five patients were included in the 
study. The age ranged was between 61-76 years old, 
with mean 65,68 ± 4,7 years and median 65 years. 
The number of male patients was 19 (76%), and 
female patients were 6 (24%). A summary of the 
baseline characteristics of the entire patient 
population and the groups is shown in Table 1.  
Table 1. Patient characteristics  
Characteristics  Number of Patients (n = 25) Percentage 
Gender 
Male 
Female 
 
19 
6 
 
76% 
24% 
Age, years 
Median (range) 
> 65 
≤ 65 
 
65 (61-76) 
11 
14 
 
 
44% 
56% 
LDH 
Normal 
High 
 
13 
12 
 
51,6% 
48,4% 
ECOG performance status 
0-1 
2-4 
 
15 
10 
 
60% 
40% 
Standard IPI 
Low 
Low-intermediate 
High-intermediate 
High 
 
10 
7 
6 
2 
 
40% 
28% 
24% 
8% 
Tumor response 
Complete response 
Partial response 
Progression 
 
18 
5 
2 
 
72% 
20% 
8% 
ECOG = Eastern cooperative oncology group. 
 
Diffuse Large B-Cell Lymphoma (DLBCL) is 
the most common histopathological structure 
observed on the patients (68%), continued with 
follicular lymphoma (20%), diffuse mixed small and 
large cell (8%), and large anaplastic cell (4%) (Figure 
1).  
 
Figure 1: Histopathology of NHL elderly patients 
 
LDH levels were normal in 51.6% of the 
patients and considered high in the rests (48.4%). 
Results of the chemotherapy were complete response 
is 72.2%, a partial response is 20%, and progression 
tumour is 8%. Because we used a t-test, so patient 
with partial response and progression tumour, we 
count in one group to no response therapy (Table 2). 
Table 2: Difference of LDH Level between response and no-
response patient 
Groups       N LDH (Mean ± SD t-test 
 t p 
No Response    7 781.63 ± 25  
7.47                0.001 Complete Response 18 444.30 ± 21 
 
Compared to the patients who showed good 
response to chemotherapy, patients with no response 
had significantly higher levels of LDH (OR: 13,1; 
95%CI: 1,36-126,30; p = 0,001) (Table 3). 
Table 3: Association between LDH level and therapy response 
LDH Level Therapy Response Total 
No Response Complete Response 
High 6 (42.8%) 8 (57.7%) 14 (56%) 
Normal 1 (9%) 10 (91%) 11 (44%) 
Total 7 (27.8%) 18 (72.2%) 25 (100%) 
 
 
 
Discussion 
 
Increased total serum LDH is commonly 
interpreted as reflecting high tumour burden or tumour 
aggressiveness. Increased serum LDH has a major 
prognostic as well as diagnostic significance in a 
patient with NHL, and total serum LDH is one of the 
parameters of International Prognostic Index (IPI) 
used in a patient with NHL [1], [8].  
Notably, the prognostic role of serum LDH in 
oncology has long been recognised. LDH is a key 
enzyme in the process of energy production in cancer 
cells; it catalyses the conversion of pyruvate to lactate 
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in hypoxic conditions [9], [10], [11]. Since its function 
in anaerobic metabolism, cancer cells grow even after 
their rapid proliferation that leads to low-oxygen 
conditions in the tumour microenvironment [12], [13]. 
Thus, LDH plays an important role in tumour 
progression and maintenance. 
In non-Hodgkin’s lymphoma, there has been 
only a low number of studies on serum LDH as a 
prognostic factor. Ferraris et al., in a study of 41 
patients, reported that an elevated serum LDH was 
correlated with a shorter surviva1 in al1 the 
histological types. In another study, Schneider et al. 
found that pretreatment serum LDH was the single 
most important prognostic variable for survival in 30 
patients with diffuse HL [14], [15]. We analysed 25 
consecutive elderly patients with NHL. After the R 
CHOP Chemotherapy, serum LDH was high in 14 
patients (%). Compared to the patients who showed a 
good response to chemotherapy, patients with no 
response had significantly higher levels of LDH. In our 
study, patients with increased LDH (more than 250 
U/l) experienced a poorer response to therapy.  
This study had several limitations. The 
enrolled patients were restricted to one local hospital, 
and the sample was relatively small to justify the effect 
of multiple clinical features on survival. The prognostic 
value of LDH level should be evaluated in a larger, 
multicenter setting.  
In conclusion, non-Hodgkin Lymphoma 
(NHL), a cancer of lymphocytes with a preponderance 
in sixth to the seventh decade of life range, should be 
paid on the use of additional parameters like LDH 
levels, estimation of which can be used for prognostic 
evaluation of patients with NHL. NHL patients with no 
response to chemotherapy had significantly higher 
levels of LDH than patients with good response 
patient.  
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